These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 14607311)

  • 1. Modulation of striatal serotonin and opioid receptor mRNA expression following systemic N-methyl-norsalsolinol administration.
    Moser A; Thümen A; Qadri F
    J Neurol Sci; 2003 Dec; 216(1):109-12. PubMed ID: 14607311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-methyl-norsalsolinol modulates serotonin metabolism in the rat caudate nucleus: correlation with behavioural changes.
    Thümen A; Behnecke A; Qadri F; Moser A
    Int J Neuropsychopharmacol; 2003 Mar; 6(1):35-40. PubMed ID: 12899734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
    Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the Serotonin 5-HT
    Newman-Tancredi A; Varney MA; McCreary AC
    Neurochem Res; 2018 May; 43(5):1035-1046. PubMed ID: 29572645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Bono F; Busi C; Barbon A; Missale C
    Mov Disord; 2016 Apr; 31(4):512-20. PubMed ID: 26898243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-methyl-norsalsolinol, a putative dopaminergic neurotoxin, passes through the blood-brain barrier in vivo.
    Thümen A; Behnecke A; Qadri F; Bäuml E; Thümen A; Behnecke CA; Qadri F; Bäuml E; Moser A
    Neuroreport; 2002 Jan; 13(1):25-8. PubMed ID: 11924888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the differential roles of striatal 5-HT
    Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
    Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV; Groenewegen HJ; Voorn P
    Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
    Ikeda K; Yoshikawa S; Kurokawa T; Yuzawa N; Nakao K; Mochizuki H
    Eur J Pharmacol; 2009 Oct; 620(1-3):42-8. PubMed ID: 19686730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Tomiyama M; Kimura T; Maeda T; Kannari K; Matsunaga M; Baba M
    Neurosci Res; 2005 Jun; 52(2):185-94. PubMed ID: 15893579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
    Nakazato T; Akiyama A
    Brain Res; 2002 Mar; 930(1-2):134-42. PubMed ID: 11879803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
    Tel BC; Zeng BY; Cannizzaro C; Pearce RK; Rose S; Jenner P
    Neuroscience; 2002; 115(4):1047-58. PubMed ID: 12453478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model.
    Zhang X; Andren PE; Svenningsson P
    Physiol Behav; 2007 Sep; 92(1-2):29-33. PubMed ID: 17588622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of serotonin 2A receptors in the analgesic effect of tramadol in mono-arthritic rats.
    Xie H; Dong ZQ; Ma F; Bauer WR; Wang X; Wu GC
    Brain Res; 2008 May; 1210():76-83. PubMed ID: 18417104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chronic cocaine treatment on mu- and delta-opioid receptor mRNA levels in dopaminergically innervated brain regions.
    Azaryan AV; Coughlin LJ; Búzás B; Clock BJ; Cox BM
    J Neurochem; 1996 Feb; 66(2):443-8. PubMed ID: 8592112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.